TrialWire on AI Panel at Endpoints News and Financial Times US Pharma and Biotech Summit in New York

TrialWire CEO joins industry leaders to address AI's defining moment in drug development at flagship biopharma event

New York, NY — 20 March 2026 — TrialWire, the AI-powered clinical trial patient recruitment platform, today announced that CEO and Founder Susan Fitzpatrick-Napier will participate as a panelist at the Endpoints News and Financial Times US Pharma and Biotech Summit, to be held in New York May 14, 2026. Fitzpatrick-Napier will join the session titled "AI in Pharma: Time to Deliver" — a high-stakes conversation about whether the biopharma industry can convert years of AI investment into measurable, real-world results.

The session reflects a pivotal inflection point for the industry. After several years of significant hype, capital deployment, and model-building, pharma and biotech companies are now under acute pressure from investors, regulators, and clinical teams to demonstrate that AI is generating genuine returns — not just promising ones. 2026 has emerged as the year the industry must prove its promises.

"The question is no longer whether AI belongs in drug development," said Susan Fitzpatrick-Napier, CEO and Founder of TrialWire. "The question is whether companies have embedded it into the workflows where it actually changes outcomes. In clinical trial enrollment, we're already seeing what's possible when AI moves from experiment to infrastructure. I'm looking forward to a frank conversation about where the industry is delivering, and where it still has work to do."

About the Session: AI in Pharma — Time to Deliver

The panel will address the central challenge facing biopharma's AI agenda in 2026: accountability. Key questions the session will explore include:

• Where is AI delivering measurable gains in drug discovery and development, and how is impact credibly assessed?

• How can R&D teams adopt AI at scale while maintaining scientific oversight and regulatory compliance?

• What frameworks are needed to ensure AI models are transparent and built on high-quality, unbiased data?

• How should companies manage IP, data rights, and ethical risks in AI-led R&D partnerships?

These are questions Fitzpatrick-Napier is uniquely positioned to address. Under her leadership, TrialWire has built one of the most operationally deployed AI platforms in clinical trial recruitment — one already delivering a 30–45% uplift in eligible patient referrals for lagging trials that need a reboot, reducing manual pre-screening time at sites by up to 70%, and operating with a 24-hour activation window in complex oncology, CNS, and rare disease trials.

AI That Delivers — Not Just Promises

TrialWire's inclusion on this panel reflects the growing recognition that AI's most immediate and measurable impact in biopharma is not in discovery alone — it is in the clinical execution layer where delays cost sponsors upward of $50,000 per day and where 80% of trials still face enrollment shortfalls.

Built on Salesforce Health Cloud and operating on a risk-share, pay-per-enrollment model, TrialWire deploys customized AI Agent screeners trained on each trial's specific eligibility and exclusion criteria. The platform continuously learns from patient interactions with feedback into its matching algorithms — to surface patients that traditional site networks never reach.

The platform's architecture also directly addresses the governance, transparency, and data privacy expectations that regulators and enterprise IT teams now demand — a critical dimension of the broader "time to deliver" conversation the panel will tackle.

"Investors and boards are asking harder questions about AI ROI than they were two years ago, and rightly so," said Fitzpatrick-Napier. "The companies winning right now are the ones that can point to a specific workflow, show you the before and after, and defend the data. That's the standard TrialWire holds itself to, and it's the standard I'll be advocating for on the panel."

About the Endpoints News and Financial Times US Pharma and Biotech Summit

The US Pharma and Biotech Summit, presented by Endpoints News and the Financial Times, is one of the leading executive gatherings in biopharma — convening senior leaders from across drug development, investment, and clinical operations to address the issues shaping the industry's trajectory. The event takes place in New York.

For event details and registration, visit: endpoints.news

About TrialWire

TrialWire is an AI-powered clinical trial patient recruitment platform built for sponsors, CROs, and research sites running complex, late-stage studies. The platform activates in under 24 hours and uses advanced algorithms and customised AI Agent screeners to identify, match, and pre-qualify eligible patients at scale — delivering real-time transparent data through a sophisticated portal built on Salesforce Health Cloud. TrialWire operates on a risk-share, pay-per-enrollment model. Learn more at www.trialwire.ai or contact us at www.trialwire.ai/contact.